DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency For Toxic Substances and Disease Registry

[ATSDR–133]

Availability of the Interagency Workgroup Document, a Draft Report on Multiple Chemical Sensitivity (MCS); Correction

A notice announcing the Availability of the Interagency Workgroup Document, A Draft Report on Multiple Chemical Sensitivity (MCS) was published in the **Federal Register** on August 31, 1998, (63 FR 46225). This notice is corrected as follows:

On page 46225, in the first column under **DATES**, the public comment period should be changed from October 30, 1998 to December 15, 1998.

On page 46225, in the first column under **ADDRESSES**, second paragraph, please add the MCS report is also available on the Environmental Health Policy Committee's website: http://web.health.gov/environment.

All other information and requirements of the August 31, 1998, notice remain the same.

Dated: October 21, 1998.

Donna Garland,

Acting Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 98–28800 Filed 10–27–98; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Ethics Subcommittee of the Advisory Committee to the Director, Centers for Disease Control and Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee meeting.

Name: Ethics Subcommittee of the Advisory Committee to the Director, CDC.

Time and Date: 9 a.m.–3 p.m., November 23, 1998.

Place: CDC, Building 16, Room 5126, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 25 people.

PURPOSE: This subcommittee will anticipate, identify, and propose solutions to strategic and broad ethical issues facing CDC.

Matters To Be Discussed: Agenda items will include an update from the Associate Director for Science, Dixie E. Snider, M.D., M.P.H.; a discussion on CDC's pandemic influenza plan; and ethical consultation on blinded HIV serosurveys.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Linda Kay McGowan, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE, M/S D–24, Atlanta, Georgia 30333. Telephone 404/639–7080, fax 404/639–7181, e-mail lkm3@cdc.gov.

Dated: October 22, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–28820 Filed 10–27–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Immunology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Immunology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 9, 1998, 9:45 a.m. to 5:30 p.m.

Location: Corporate Bldg., conference room 020B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: Louise E. Magruder, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1293, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12516. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss, make recommendations, and vote on a premarket approval application for a fluorescence *in situ* hybridization assay used in the detection of amplification of the HER–2/neu gene from subjects with node positive, stage II breast cancer to aid in the assessment of response to adjuvant therapy.

Procedure: On November 9, 1998, from 10:15 a.m. to 5:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 2, 1998. Oral presentations from the public will be scheduled between approximately 10:30 a.m. and 11 a.m. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 2, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 9, 1998, from 9:45 a.m. to 10:15 a.m., the meeting will be closed to the public to permit FDA to present to the committee trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) regarding pending and future device submissions.

FDA regrets that it was unable to publish this notice 15 days prior to the November 9, 1998, Immunology Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Immunology Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 22, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–28900 Filed 10–23–98; 3:31 pm]

BILLING CODE 4160–01–F